Breast cancer, soft tissue cancer, stomach cancer, bowel cancer, liver cancer, lung cancer, cervical cancer,
Conditions
Interventions
single arm:Nk-1 receptor antagonist, 5-ht3 receptor antagonist and dexamethasone antiemetic regimen
Sponsors
Affiliated Tumor Hospital of Guangxi Medical University
Eligibility
Sex/Gender
All
Age
18 Years to 70 Years
Inclusion criteria
Inclusion criteria: 1. Patient aged 18 to 70 years male or females; 2. Patient with ECOG =90 g/L,WBC>=3.0x10^9/L,ANC>=1.5x10^9/L, PLT>=80x10^9/L; TBIL50 ml/min (Cockcroft-Gault formula); 8. Last cycle of chemotherapy was completed >=3 weeks prior to baseline; 9. Women of childbearing age are willing to using appropriate methods of contraception during the test and 8 weeks after having the last experimental drug, and should have a pregnancy check before test if necessary, the result should be negative; 10. Patient were willing to join in this study, sign the informed consent, good adherence, and cooperate with the follow-up.
Exclusion criteria
Exclusion criteria: 1. Pregnant or nursing female patient; need radiotherapy during our study going on; 2. Patient with gastrointestinal tract obstruction; 3. Patient with seriously heart disease, liver and kidney diseases, or metabolic dysfunction; 4. Patient with epilepsy, or using psychiatric drugs or sedative; 5. Patient Used antiemeticwithin 24hours of starting the study treatment, or vomited before chemotherapy; 6. Patient with metastatic brain tumor, vomitingbecause of intracranial hypertension; 7. Patient with irritability of 5-HT3 receptor antagonist; 8. Patient with Contraindications on chemotherapy; 9. Being or 4 weeks prior to the starting of the study involved in other drug clinical trial.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| According to the international evaluation system for adverse reactions to chemotherapy drugs (CTCAE) version 4.03. Nausea is defined as a condition characterized by nausea and/or an urgent need for vomiting.;Complete remission rate (CR): number of CINV complete remission patients/number of chemotherapy patients x100%; CINV complete remission was defined as (CTCAE) version 4.03, nausea and vomiting grade 0 (no nausea and vomiting).;Adverse reactions: adverse events and laboratory tests were graded according to NCI CTC AE 4.0, and special attention should be paid to early withdrawal from the study as well as vital signs (such as blood pressure, body temperature, etc.), intestinal obstruction, intractable hiccups, uncontrollable headaches, etc.; | — |
Countries
China
Contacts
Public ContactXie Weimin
Affiliated Tumor Hospital of Guangxi Medical University
Outcome results
None listed